Quarterly ResultMay 6, 2026, 04:19 PM
Standard BioTools Q1 Net Income $127.1M on SomaScan Divestment
AI Summary
Standard BioTools reported a net income of $127.1 million for Q1 2026, a significant improvement from a net loss of $26.0 million in Q1 2025. This was primarily driven by the completion of the SomaScan Business divestment to Illumina on January 30, 2026, which generated $363.2 million in net cash and a pre-tax gain of $172.3 million. Continuing operations saw total revenue increase by 4.5% to $21.1 million, while the net loss from continuing operations improved to $14.6 million.
Key Highlights
- Net income was $127.1M in Q1 2026, up from a $(26.0)M loss in Q1 2025.
- SomaScan Business divestment closed, yielding $363.2M cash and $25.0M receivable.
- Pre-tax gain on SomaScan sale was $172.3M, contributing to discontinued operations.
- Total revenue from continuing operations increased 4.5% to $21.1M.
- Net loss from continuing operations improved to $(14.6)M from $(23.4)M.
- Cash and cash equivalents rose to $265.8M from $120.9M at Dec 31, 2025.
- R&D expenses decreased 61.2% to $2.1M; SG&A fell 37.6% to $18.6M.
- EMEA revenue was $9.4M, Americas $7.7M, and Asia-Pacific $4.0M.